Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1y antibodies in adults with XXXX .

@entity1 @entity35837 @entity6017 @entity625 @entity8820 @entity1569 @entity5 @entity2407 @entity272 @entity401 @entity4841 @entity10673
BACKGROUND: Antibodies against transcriptional intermediary factor (TIF)-1y are associated with @entity5 in @entity6017 ( @entity6017 ). Identification of clinical findings associated with anti- @entity35837 y antibodies in @entity6017 is a high priority for both @entity1 diagnosis and risk assessment. OBJECTIVE: We sought to define the clinical phenotype of patients with anti-TIF-1y @entity6017 . METHODS: Using a novel, sensitive, and specific assay for anti-TIF-1y antibodies, we retrospectively tested plasma from 134 adult @entity1 with @entity6017 and examined associations between anti- @entity35837 y antibodies and particular clinical and laboratory features. RESULTS: In all, 55 (41%) @entity1 had autoantibodies to TIF-1y. Anti-TIF-1y positive @entity1 were less likely to have systemic features including @entity401 , @entity2407 , and @entity625 / @entity4841 . @entity1 with TIF-1y autoantibodies had more extensive skin involvement, and some @entity1 manifested characteristic findings including palmar @entity8820 papules, @entity1569 -like lesions and a novel finding of hypopigmented and @entity10673 ("red on white") patches. LIMITATIONS: This was a retrospective study from a single tertiary referral center. CONCLUSION: TIF-1y is the most commonly targeted @entity6017 -specific autoantigen in adults in a large US cohort. Although these @entity1 tend to have less systemic involvement, their @entity272 is often extensive and characteristic. Recognition of cutaneous findings in anti- @entity35837 y positive @entity1 may allow more accurate and timely diagnosis and effective treatment of @entity1 with @entity6017 .
